| Literature DB >> 33973185 |
Maryam Fotouhi1,2, Elham Samami1,3, Sahar Mohseni1,4, Amir Nasrollahizadeh1,2, Mohammad Haddadi1,2, Mona Mirbeyk1,2, Amene Saghazadeh1,5, Nima Rezaei6,7,8.
Abstract
Novel coronavirus disease 2019 (COVID-19) has posed a crucial hazard to global health. The new species share similarities with the two previously emerged entities: severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) that have caused outbreaks in 2002 and 2012, respectively. Interestingly, all of these coronaviruses can cause potentially fatal respiratory syndromes, though behave differently in patients with cancer compared to patients without cancer. Accordingly, the present chapter aims to, through a systematic investigation, estimate the prevalence of cancer among COVID-19, SARS, and MERS confirmed cases. Our analysis based on data from 78 studies with SARS, MERS, and COVID-19 confirmed cases showed that the prevalence of cancer (4.94%) stands at fourth place after hypertension (20.8%), diabetes (11.39%), and cardiovascular diseases (7.46%). According to the findings of the present study, comorbidities are significantly more common in patients with MERS compared to patients with COVID-19 and SARS, and this was the cancer case as well. Further studies need to address whether or not patients with coronaviruses and cancer are different from patients with coronaviruses without cancer in terms of clinical manifestations, laboratory findings, outcomes, and men to women ratio.Entities:
Keywords: COVID-19; Cancer; Comorbidities; MERS; SARS; Systematic review
Mesh:
Year: 2021 PMID: 33973185 DOI: 10.1007/978-3-030-63761-3_17
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622